Literature DB >> 24917358

Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia.

A F Muggen1, S Y Pillai2, L P Kil2, M C van Zelm1, J J M van Dongen1, R W Hendriks2, A W Langerak1.   

Abstract

On the basis of somatic hypermutation status of their B-cell antigen receptor (BCR) genes, chronic lymphocytic leukemia (CLL) patients can be divided into unmutated CLL (U-CLL) or mutated CLL (M-CLL). Approximately 30% of CLL patients express a stereotypic BCR, which may indicate that specific antigenic stimulation is driving CLL pathogenesis. Recently, it was reported that BCRs from CLL cells are capable of antigen-independent, cell-autonomous signaling, through recognition of an internal framework 2 (FR2) BCR epitope. We hypothesized that the level of cell-autonomous signaling may differ between CLL subgroups. Therefore, we analyzed Ca(2+) signaling in a series of primary stereotypic or heterogeneous U-CLL and M-CLL (n=68) and healthy controls (n=14). We confirmed that basal Ca(2+) signaling in CLL cells is higher than in normal B cells. Interestingly, we found that basal signaling was particularly increased in M-CLL. The degree of basal signaling did not correlate with membrane immunoglobulin levels, HCDR3 characteristics or FR2/FR3 sequence. We conclude that the level of basal Ca(2+) signaling is not uniformly enhanced in CLL B cells, but is associated with CLL immunoglobulin heavy chain V mutational status, reflecting a distinct cellular origin and possibly a different anergic state induced by repetitive or continuous antigen binding in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24917358     DOI: 10.1038/leu.2014.188

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

1.  Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.

Authors:  C Ian Mockridge; Kathleen N Potter; Isla Wheatley; Louise A Neville; Graham Packham; Freda K Stevenson
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

2.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

3.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.

Authors:  C Haferlach; F Dicker; S Schnittger; W Kern; T Haferlach
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

4.  Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.

Authors:  Alessandra Cesano; Omar Perbellini; Erik Evensen; Charles C Chu; Federica Cioffi; Jason Ptacek; Rajendra N Damle; Roberto Chignola; James Cordeiro; Xiao-jie Yan; Rachael E Hawtin; Ilaria Nichele; Jodi R Ware; Chiara Cavallini; Ornella Lovato; Roberta Zanotti; Kanti R Rai; Nicholas Chiorazzi; Giovanni Pizzolo; Maria T Scupoli
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

5.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

6.  IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.

Authors:  M Coscia; F Pantaleoni; C Riganti; C Vitale; M Rigoni; S Peola; B Castella; M Foglietta; V Griggio; D Drandi; M Ladetto; A Bosia; M Boccadoro; M Massaia
Journal:  Leukemia       Date:  2011-03-04       Impact factor: 11.528

7.  Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.

Authors:  Marta Muzio; Benedetta Apollonio; Cristina Scielzo; Michela Frenquelli; Irene Vandoni; Vassiliki Boussiotis; Federico Caligaris-Cappio; Paolo Ghia
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Targeting B-cell anergy in chronic lymphocytic leukemia.

Authors:  Benedetta Apollonio; Cristina Scielzo; Maria Teresa Sabrina Bertilaccio; Elisa Ten Hacken; Lydia Scarfò; Pamela Ranghetti; Freda Stevenson; Graham Packham; Paolo Ghia; Marta Muzio; Federico Caligaris-Cappio
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

10.  Endogenous antigen tunes the responsiveness of naive B cells but not T cells.

Authors:  Julie Zikherman; Ramya Parameswaran; Arthur Weiss
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

View more
  10 in total

1.  Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Authors:  Silvia Mele; Stephen Devereux; Andrea G Pepper; Elvira Infante; Anne J Ridley
Journal:  Blood Adv       Date:  2018-07-10

2.  CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.

Authors:  Soizic Garaud; Taher E Taher; Marjolaine Debant; Miguel Burgos; Sarra Melayah; Christian Berthou; Kaushal Parikh; Jacques-Olivier Pers; Damien Luque-Paz; Gilles Chiocchia; Maikel Peppelenbosch; David A Isenberg; Pierre Youinou; Olivier Mignen; Yves Renaudineau; Rizgar A Mageed
Journal:  Cell Mol Immunol       Date:  2016-08-08       Impact factor: 11.530

3.  Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Authors:  Sophie A Herbst; Mattias Vesterlund; Alexander J Helmboldt; Rozbeh Jafari; Ioannis Siavelis; Matthias Stahl; Eva C Schitter; Nora Liebers; Berit J Brinkmann; Felix Czernilofsky; Tobias Roider; Peter-Martin Bruch; Murat Iskar; Adam Kittai; Ying Huang; Junyan Lu; Sarah Richter; Georgios Mermelekas; Husen Muhammad Umer; Mareike Knoll; Carolin Kolb; Angela Lenze; Xiaofang Cao; Cecilia Österholm; Linus Wahnschaffe; Carmen Herling; Sebastian Scheinost; Matthias Ganzinger; Larry Mansouri; Katharina Kriegsmann; Mark Kriegsmann; Simon Anders; Marc Zapatka; Giovanni Del Poeta; Antonella Zucchetto; Riccardo Bomben; Valter Gattei; Peter Dreger; Jennifer Woyach; Marco Herling; Carsten Müller-Tidow; Richard Rosenquist; Stephan Stilgenbauer; Thorsten Zenz; Wolfgang Huber; Eugen Tausch; Janne Lehtiö; Sascha Dietrich
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

4.  STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.

Authors:  Marjolaine Debant; Miguel Burgos; Patrice Hemon; Paul Buscaglia; Tinhinane Fali; Sarra Melayah; Nelig Le Goux; Christophe Vandier; Marie Potier-Cartereau; Jacques-Olivier Pers; Adrian Tempescul; Christian Berthou; Cristina Bagacean; Olivier Mignen; Yves Renaudineau
Journal:  J Immunother Cancer       Date:  2019-04-23       Impact factor: 13.751

5.  Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-κB pathway.

Authors:  Ruud W J Meijers; Alice F Muggen; Leticia G Leon; Maaike de Bie; Jacques J M van Dongen; Rudi W Hendriks; Anton W Langerak
Journal:  Haematologica       Date:  2019-05-16       Impact factor: 9.941

6.  SIRPα on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production.

Authors:  Katka Franke; Saravanan Y Pillai; Mark Hoogenboezem; Marion J J Gijbels; Hanke L Matlung; Judy Geissler; Hugo Olsman; Chantal Pottgens; Patrick J van Gorp; Maria Ozsvar-Kozma; Yasuyuki Saito; Takashi Matozaki; Taco W Kuijpers; Rudi W Hendriks; Georg Kraal; Christoph J Binder; Menno P J de Winther; Timo K van den Berg
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 7.  Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Authors:  Yu Nie; Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-06-27

8.  New human single chain anti-idiotypic antibody against benzo[a]pyrene.

Authors:  Artem E Studennikov; Valentin A Ustinov; Vera V Morozova; Nina V Tikunova; Andrey N Glushkov
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

9.  Genome-wide DNA methylation profiling integrated with gene expression profiling identifies PAX9 as a novel prognostic marker in chronic lymphocytic leukemia.

Authors:  Lata Rani; Nitin Mathur; Ritu Gupta; Ajay Gogia; Gurvinder Kaur; Jaspreet Kaur Dhanjal; Durai Sundar; Lalit Kumar; Atul Sharma
Journal:  Clin Epigenetics       Date:  2017-05-30       Impact factor: 6.551

10.  Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.

Authors:  Simar Pal Singh; Saravanan Y Pillai; Marjolein J W de Bruijn; Ralph Stadhouders; Odilia B J Corneth; Henk Jan van den Ham; Alice Muggen; Wilfred van IJcken; Erik Slinger; Annemieke Kuil; Marcel Spaargaren; Arnon P Kater; Anton W Langerak; Rudi W Hendriks
Journal:  Oncotarget       Date:  2017-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.